Avani Mangoli

Journal Article Nat Commun · January 25, 2024 Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional immune signaling. ... Full text Link to item Cite

Ataxia-telangiectasia mutated ( Atm ) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy.

Journal Article bioRxiv · October 20, 2023 Diffuse midline gliomas (DMGs) are lethal brain tumors characterized by p53-inactivating mutations and oncohistone H3.3K27M mutations that rewire the cellular response to genotoxic stress, which presents therapeutic opportunities. We used RCAS/tv-a retrovi ... Full text Link to item Cite

Hematology of childhood and adolescence

Chapter · January 1, 2023 Hematologic homeostasis requires an intricate interaction of red blood cells, white blood cells, platelets, and coagulation factors. Normal parameters vary with age, sex, and race. Underlying causes for hematologic abnormalities in children may range from ... Full text Cite

Oncology of childhood and adolescence

Chapter · January 1, 2023 Childhood and adolescent cancer are broadly categorized into leukemia, lymphoma, extracranial solid tumors, and central nervous system (CNS) tumors. Many of these cancers can present as oncologic emergencies, which are important to recognize. Supportive ca ... Full text Cite

Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care.

Journal Article Pediatr Blood Cancer · July 2022 BACKGROUND: Maintaining dose-dense, interval-compressed chemotherapy improves survival in patients with Ewing sarcoma but is limited by myelosuppression. Romiplostim is a thrombopoietin receptor agonist that may be useful in the treatment of chemotherapy-i ... Full text Link to item Cite